BioTime finalizes a deal to buy Geron’s defunct human embryonic stem cell assets.
Advertisement
The Scientist
Most Recent
Researchers in Vienna are starting a Phase I trial on the first ever vaccine with a potential to treat the neurodegenerative disease.
Page 1 of 1
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
